Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) in China to commence a clinical study of its Category 1 drug candidate, HS-10501. The study aims to assess the efficacy and safety of the drug in patients with type 2 diabetes and adult obesity.
At this stage, no further details about the molecular composition or specific mechanisms of action of HS-10501 have been disclosed by the company.- Flcube.com
